AXGT News and Press, Axovant Gene Therapies Ltd. From 04/24/20

NEW YORK and BASEL, Switzerland, April 24, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. a clinical-stage company developing innovative gene therapies for neurological diseases, today announced that it had prepaid in full its $15.7 million outstanding loan from Hercules Capital, Inc....

Axovant Gene Therapies (NASDAQ: AXGT ) initiated with Overweight rating and $11 (209% upside) price target at Cantor Fitzgerald. More news on: Axovant Gene Therapies Ltd., Biohaven Pharmaceutical Holding Company Ltd., Coherus BioSciences, Inc., Healthcare stocks news, Stocks on the move, ,...

Partnership to reduce barriers to genetic diagnosis through sponsored testing for lysosomal storage diseases Initiative supports identification of patients with GM1 and GM2 gangliosidosis who are currently misdiagnosed or undiagnosed NEW YORK and BASEL, Switzerland, April 15, 20...

Completed dosing of all patients in second cohort of AXO-Lenti-PD dose escalation study At present, Company remains on track to achieve key 2020 milestones NEW YORK and BASEL, Switzerland, April 08, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-s...

NEW YORK and BASEL, Switzerland, March 31, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases, today announced that management will participate in the virtual Guggenheim Healthcare Talk...

Stating the obvious, Baird analysts have created three lists of healthcare companies that may be worth a look considering their attractive valuations or relatively strong capitalizations amid the COVID-19 selloff. More news on: IDEAYA Biosciences, Inc., Surface Oncology, Inc., Jounce Thera...

NEW YORK and BASEL, Switzerland, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT) ("Axovant") today announced the closing of its previously announced underwritten public offering of 16,631,336 common shares, including the full exercise of the underwriters’...

Tivity Health (NASDAQ: TVTY )  -39%  on Q4 earnings . More news on: Tivity Health, Inc., Six Flags Entertainment Corporation, BioXcel Therapeutics, Inc., Stocks on the move, Read more ...

Axovant Gene Therapies (NASDAQ: AXGT ) prices its public offering of ~14M common shares at $3.75 per shares. Underwriters' over-allotment is an additional 2.6M shares. Gross proceeds should be ~$52.6M. More news on: Axovant Gene Therapies Ltd., Healthcare stocks news, Stocks on the move,...

NEW YORK and BASEL, Switzerland, Feb. 19, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (Nasdaq: AXGT) ("Axovant") today announced the pricing of its underwritten public offering of 14,031,336 of its common shares at a price to the public of $3.75 per share. In addition, an...